Francesca Cola-Di

Brescia, 25123, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study.

Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study.

Journal: Journal of neurology

Published: January 09, 2026

Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.

Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: April 08, 2025

Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.

Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.

Journal: Toxins

Published: October 08, 2023

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study.

Journal: Journal of neurology

Published: May 07, 2023

An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.

An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.

Journal: European journal of neurology

Published: January 09, 2023

Photophobia and migraine outcome during treatment with galcanezumab.

Photophobia and migraine outcome during treatment with galcanezumab.

Journal: Frontiers in neurology

Published: November 02, 2022

Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab.

Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab.

Journal: European neurology

Published: August 26, 2022

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation.

Post COVID-19 vaccination headache: A clinical and epidemiological evaluation.

Journal: Frontiers in pain research (Lausanne, Switzerland)

Published: July 14, 2022

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: April 14, 2022

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.

Journal: Journal of neurology

Published: March 20, 2022

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.

Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.

Journal: European journal of neurology

Published: November 09, 2021

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination.

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination.

Journal: Journal of neurology

Published: October 08, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026